在Trichoplusia ni中对P450超级家族的全基因组鉴定和对HDAC抑制剂的抗性在体表达
Arsalan Ahmad1, Adnan Sami2, Muhammad Zeshan Haider3
1Department of Entomology, Faculty of Agricultural Sciences, University of the Punjab, P.O BOX. 54590, Lahore, Pakistan.
Scientific reports
|August 22, 2025
概括
这项研究在白菜中发现了19个P450基因 (CYP450),其中CYP4C1-1等关键基因有助于对HDAC抑制剂的耐药性. 这些发现为创新的害虫控制策略提供了目标.
科学领域:
- 分子生物学
- 昆虫学
- 农业科学
背景情况:
- 卷心菜 (Trichoplusia ni) 是一个重要的农业害虫,造成经济损失.
- 细胞染色体P450 (CYP450) 基因对代谢过程至关重要,但在T.
- 了解CYP450对于管理抗虫剂和作物保护至关重要.
研究的目的:
- 发现和描述白菜 (Trichoplusia ni) 中的P450基因.
- 研究这些CYP450基因在代谢活动中的作用,包括杀虫剂解毒和耐药性.
- 鉴定涉及对HDAC抑制剂耐药性的特定CYP450基因.
主要方法:
- 在基因表达分析中,用于分析T. ni的CYP450基因表达.
- 在各种代谢过程中涉及的19个CYP450基因的识别和表征.
- 专注于与脂肪酸代谢,抵抗机制,植物毒素反应和杀虫剂排毒相关的基因.
主要成果:
- 在T. ni中确定并研究了19个CYP450基因.
- 发现关键基因,包括CYP4C1-1,CYP4C1-like-1和CYP4C1-2,对抗HDAC抑制剂 (硫黄,Trichostatin A) 的耐药性至关重要.
- 这些基因在化学处理中发挥着重要作用,
结论:
- 已识别的CYP450基因对于T. ni的代谢过程和抗虫剂性至关重要.
- 特定的基因如CYP4C1-1,CYP4C1-like-1和CYP4C1-2是理解和管理HDAC抑制剂耐药性的关键目标.
- 这项研究为开发新的害虫控制策略提供了宝贵的遗传洞察力.
相关概念视频
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


